While COVID-19 remains a top research priority globally for government and nonprofit entities in partnership with biopharma companies, deal activity also is heavily focused on other infectious diseases, such as smallpox and influenza.
In fact, only about half of the infectious disease deals between biopharma and nonprofits are focused on the current pandemic. The others, 57 in total, are working toward solutions for anthrax, HIV, malaria, respiratory infections, chickenpox, dengue fever, yellow fever, monkeypox and others.
Through mid-September, BioWorld has tracked 481 deals between biopharma companies and nonprofit or government entities (bio/nonprofit). The deals are worth a combined $7.54 billion. A total of 117 worth $7.27 billion are for infectious disease indications.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.